Disease on EC 1.1.1.88 - hydroxymethylglutaryl-CoA reductase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acute Coronary Syndrome
Early statin therapy for acute coronary syndromes.
Potential nontraditional applications of statins.
Acute Lung Injury
A Randomized Clinical Trial of Hydroxymethylglutaryl-CoA reductase Inhibition for Acute Lung Injury (The HARP study).
Diabetes, insulin, and development of acute lung injury.
Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP-2) trial: study protocol for a randomized controlled trial.
Alzheimer Disease
Statins reduce amyloid-beta production through inhibition of protein isoprenylation.
The role of cholesterol and statins in Alzheimer's disease.
Angina Pectoris
Cholesterol reduction yields clinical benefits: meta-analysis including recent trials.
Angina, Unstable
Early statin therapy for acute coronary syndromes.
Aortic Valve Stenosis
Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.
Arthritis, Rheumatoid
Inhibition of protein geranylgeranylation induces apoptosis in synovial fibroblasts.
Atherosclerosis
Comparison of the effects of atorvastatin versus simvastatin on subclinical atherosclerosis in primary preventionas determined by electronbeam tomography.
Effect of statin therapy before Q-wave myocardial infarction on myocardial perfusion.
Geranylgeraniol prevents the cytotoxic effects of mevastatin in THP-1 cells, without decreasing the beneficial effects on cholesterol synthesis.
Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae.
Inhibitory effect of co-administration of atorvastatin and endothelin-1 receptor antagonist on the progression of atherosclerosis in rabbit.
Breast Neoplasms
Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia.
Carcinogenesis
HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc.
Inhibitory effects of beta-carotene and vitamin a during the progression phase of hepatocarcinogenesis involve inhibition of cell proliferation but not alterations in DNA methylation.
Carcinoma
3-Hydroxy-3-methylglutaryl coenzyme A reductase activity and low-density lipoprotein receptor expression in diffuse-type and intestinal-type human gastric cancer.
Carcinoma, Hepatocellular
Loss of feedback control of hydroxymethylglutaryl coenzyme A reductase in hepatomas.
Treatment of HCC with pravastatin, octreotide, or gemcitabine--a critical evaluation.
Cardiomegaly
Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation.
Cardiomyopathy, Hypertrophic
HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study.
Cardiovascular Diseases
Do statins have a role in the prevention of age-related macular degeneration?
Hypertriglyceridemia: associated risks and effect of drug treatment.
Impact of statins on risk of stroke: a meta-analysis.
Magnitude of HDL cholesterol variation after high-dose atorvastatin is genetically determined at the LDL receptor locus in patients with homozygous familial hypercholesterolemia.
Reversal of statin toxicity to human lymphocytes in tissue culture.
Cataract
Risk of cataract in patients treated with statins.
The eye lens evaluation of the atorvastatin-treated white rat.
Colorectal Neoplasms
Statin use is associated with a reduced incidence of colorectal adenomatous polyps.
Coronary Artery Disease
Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease.
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day.
Coronary Disease
Cholesterol reduction yields clinical benefits: meta-analysis including recent trials.
Effects of a global risk educational tool on primary coronary prevention: the Atherosclerosis Assessment Via Total Risk (AVIATOR) study.
Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys.
Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE)
The benefits of statin therapy--what questions remain?
Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study.
Delirium
Evaluating early administration of the hydroxymethylglutaryl-CoA reductase inhibitor simvastatin in the prevention and treatment of delirium in critically ill ventilated patients (MoDUS trial): study protocol for a randomized controlled trial.
Demyelinating Diseases
Cerebroside synthesis as a measure of the rate of remyelination following cuprizone-induced demyelination in brain.
Diabetes Mellitus
Angiotensin-converting enzyme insertion/deletion polymorphism does not influence the restenosis rate after coronary stent implantation.
Diabetes, insulin, and development of acute lung injury.
Risk of new-onset diabetes associated with statin use.
Diabetes Mellitus, Type 2
Effect of treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM.
Evidence for metabolic aberrations in asymptomatic persons with type 2 diabetes after initiation of simvastatin therapy.
Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease.
Diabetic Nephropathies
Antiproliferative effect of fluvastatin and thiazolidinedione in mesangial cells of diabetic rats.
Diabetic Retinopathy
Association of statin use with the risk of developing diabetic retinopathy.
Dyslipidemias
Effects of niacin on glucose control in patients with dyslipidemia.
New insights into lipid metabolism in chronic kidney disease: what are the practical implications?
[Dynamics of microrheologic properties of erythrocytes in patients with arterial hypertension and dyslipidemia treated with atorvastatin].
[Treatment with hydroxymethylglutaryl coenzyme-A-reductase inhibitors in elderly patients: is it necessary?]
Gallstones
Effect of CS-514, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in hamsters.
Inhibitory effects of pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in prairie dogs.
[Effects of a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase on cholesterol gallstone formation in prairie dogs]
Glioblastoma
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.
Glioma
Lipid metabolism impairment in human gliomas: expression of peroxisomal proteins in human gliomas at different grades of malignancy.
Heart Failure
Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction.
Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure.
Hypercholesterolemia
Activity profile of gemfibrozil on the major plasma lipoprotein parameters.
Cholesterol reduction yields clinical benefits: meta-analysis including recent trials.
Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia.
Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients.
Elevated pregnancy-associated plasma protein-a in sera from type 2 diabetic patients with hypercholesterolemia: associations with carotid atherosclerosis and toe-brachial index.
Hydroxymethylglutaryl coenzyme A reductase inhibitors as monotherapy in the treatment of hypercholesterolemia.
Hypertension and lipids: lipid factors in the hypertension syndrome.
Interactions between hypercholesterolemia and hypertension: implications for therapy.
Synergistic interaction of lovastatin and paclitaxel in human cancer cells.
Targeting tumor cell metabolism with statins.
The spectrum of statin therapy in hyperlipidemic children.
Hyperglycemia
Diabetes, insulin, and development of acute lung injury.
Hyperinsulinism
Effects of insulin on cholesterol synthesis in type II diabetes patients.
Hyperlipidemias
Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients.
Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients.
New insights into lipid metabolism in chronic kidney disease: what are the practical implications?
[Use of hydroxymethylglutaryl coenzyme A reductase inhibitors in patients with post-transplantation hyperlipemia]
Hyperlipoproteinemia Type II
Inhibition of exercise-induced shortening of bleeding time by fish oil in familial hypercholesterolemia (type IIa).
Magnitude of HDL cholesterol variation after high-dose atorvastatin is genetically determined at the LDL receptor locus in patients with homozygous familial hypercholesterolemia.
Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans.
Suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and of incorporation of acetate into cholesterol in homozygous hypercholesterolemic fibroblasts by ferritin-low density lipoprotein conjugates.
The influence of mevinolin on the adrenal cortical response to corticotropin in heterozygous familial hypercholesterolemia.
Hypertension
Angiotensin-converting enzyme insertion/deletion polymorphism does not influence the restenosis rate after coronary stent implantation.
Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia.
[Dynamics of microrheologic properties of erythrocytes in patients with arterial hypertension and dyslipidemia treated with atorvastatin].
Hypertriglyceridemia
Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients.
Lipid-lowering therapy and macrovascular disease in diabetes mellitus.
Infection
Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro.
Further investigations of race:cultivar-specific induction of enzymes related to phytoalexin biosynthesis in soybean roots following infection with Phytophthora megasperma f.sp. glycinea.
Insulin Resistance
Differential metabolic effects of distinct statins.
Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients.
Kidney Failure, Chronic
Effect of Hydroxymethylglutaryl-CoA Reductase Inhibitors on Low-density Lipoprotein Cholesterol, Interleukin-6, and High-Sensitivity C-Reactive Protein in End-stage Renal Disease.
Leukemia
Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo.
Leukemia, Myeloid
Inhibition of hydroxymethylglutaryl coenzyme A reductase activity induces a paradoxical increase in DNA synthesis in myeloid leukemia cells.
Muscular Diseases
Acute myopathy in a patient with concomitant use of pravastatin and colchicine.
Myopathy due to statin/fibrate use in the Netherlands.
Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.
Rhabdomyolysis following clarithromycin monotherapy.
[Rhabdomyolysis as a side effect of simvastatin treatment]
Myalgia
Coenzyme Q10: a therapy for hypertension and statin-induced myalgia?
Myocardial Infarction
Cholesterol reduction yields clinical benefits: meta-analysis including recent trials.
Early statin therapy for acute coronary syndromes.
Effect of statins pretreatment on periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention: a meta-analysis.
Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction.
Impact of hydroxymethylglutaryl coenzyme a reductase inhibition on left ventricular remodeling after myocardial infarction: an experimental serial cardiac magnetic resonance imaging study.
Impact of hydroxymethylglutaryl coenzyme A reductase inhibition on left ventricular remodeling in patients with acute anterior myocardial infarction after primary coronary angioplasty.
Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction.
Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE)
[Treatment with hydroxymethylglutaryl coenzyme-A-reductase inhibitors in elderly patients: is it necessary?]
Neoplasms
A discoordinate increase in the cellular amount of 3-hydroxy-3-methylglutaryl-CoA reductase results in the loss of rate-limiting control over cholesterogenesis in a tumour cell-free system.
Biochemical effects, hypolipidemic and anti-inflammatory activities of Artemisia vulgaris extract in hypercholesterolemic rats.
Combination chemoprevention: future direction of colorectal cancer prevention.
Effects of pravastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, on two human tumour cell lines.
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.
HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc.
Lipid composition and 3-hydroxy-3-methylglutaryl-CoA reductase activity of acinar cell carcinoma of rat pancreas.
Lipid metabolism impairment in human gliomas: expression of peroxisomal proteins in human gliomas at different grades of malignancy.
Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies.
Regulation of cholesterol metabolism in a slow-growing hepatoma in vivo.
Regulation of cholesterol synthesis in four colonic adenocarcinoma cell lines.
Simvastatin enhances induction of inducible nitric oxide synthase in 3T3-L1 adipocytes.
Nephrotic Syndrome
New aspects of the treatment of nephrotic syndrome.
Should hyperlipidemia in children with the nephrotic syndrome be treated?
Peripheral Arterial Disease
Potential nontraditional applications of statins.
Proteinuria
Effect of simvastatin on plasma lipid and lipoprotein concentrations and low-density lipoprotein metabolism in the nephrotic syndrome.
Renal Insufficiency
Associated effect of hepatic hydroxymethylglutaryl coenzyme A reductase + angiotensin converting enzyme inhibitors on the progression of renal failure in hypertensive subjects.
Respiratory Distress Syndrome, Adult
Diabetes, insulin, and development of acute lung injury.
Rhabdomyolysis
Overexpression of neural cell adhesion molecule in regenerative muscle fibers in 3-hydroxy-3-methylglutaryl coenzyme: A reductase inhibitor-induced rhabdomyolysis.
Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.
Rhabdomyolysis following clarithromycin monotherapy.
[Rhabdomyolysis as a side effect of simvastatin treatment]
Sepsis
Increased rates of hepatic cholesterogenesis and fatty acid synthesis in septic rats in vivo: evidence for the possible involvement of insulin.
Stomach Neoplasms
3-Hydroxy-3-methylglutaryl coenzyme A reductase activity and low-density lipoprotein receptor expression in diffuse-type and intestinal-type human gastric cancer.
Stroke
High-dose lovastatin for acute ischemic stroke: results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART).
Impact of statins on risk of stroke: a meta-analysis.
Inflammatory markers and stroke.
Potential nontraditional applications of statins.
Stroke prevention: what's new?
[Treatment with hydroxymethylglutaryl coenzyme-A-reductase inhibitors in elderly patients: is it necessary?]
Subarachnoid Hemorrhage
Effect of prior statin use on functional outcome and delayed vasospasm after acute aneurysmal subarachnoid hemorrhage: a matched controlled cohort study.
Statin treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
Ureteral Obstruction
Fluvastatin reduces renal fibroblast proliferation and production of type III collagen: therapeutic implications for tubulointerstitial fibrosis.
Vaccinia
Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro.
Vascular Calcification
Accelerated atherosclerotic calcification and Monckeberg's sclerosis: a continuum of advanced vascular pathology in chronic kidney disease.
Amplification of atherosclerotic calcification and Mönckeberg's sclerosis: a spectrum of the same disease process.
Vascular System Injuries
Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury.
Vasospasm, Intracranial
Statin treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
Virus Diseases
Increased hydroxymethylglutaryl coenzyme A reductase activity during respiratory syncytial virus infection mediates actin dependent inter-cellular virus transmission.